Hence, SCD1 is a promising candidate for targeted drug development in STK11/KEAP1 co-mutant lung adenocarcinoma and ameliorated the drug resistance by inducing ferroptosis 44. This evidence concerns the gene KEAP1 and lung adenocarcinoma.